GlassScriptPhysician profile
Amanda R Self
NPI 1609276732
$8,254.82
in general payments reported to CMS, 2019-2025
41 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,892 · 2022: $1,790 · 2023: $928 · 2024: $1,735 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,572.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,071.89 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $869.27 | 2021-2025 | |
| Novo Nordisk INC | $814.45 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $711.21 | 2021-2025 | |
| Amgen INC. | $614.17 | 2021-2025 | Evenity, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $595.42 | 2021-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $319.52 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $317.91 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $274.57 | 2021-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.03 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $267.67 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $263.17 | 2021-2025 | Gardasil 9, Capvaxive |
| Sanofi-Aventis U.S. LLC | $247.72 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.78 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $158.43 | 2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $129.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $101.20 | 2023-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $82.87 | 2021 | |
| Axsome Therapeutics, INC. | $79.02 | 2025 | Auvelity |
| Dexcom, INC. | $74.18 | 2023-2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $69.26 | 2022-2025 | Zoryve |
| Eisai INC. | $67.59 | 2021-2025 | |
| Corium, LLC | $62.57 | 2025 | Azstarys |
| Upsher-Smith Laboratories LLC | $61.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $60.53 | 2022-2024 | |
| Irhythm Technologies, INC. | $58.86 | 2024 | Zio Monitor, Zio Xt Patch |
| Abbott Laboratories | $58.66 | 2021-2024 | Mitraclip |
| Ironwood Pharmaceuticals, INC | $48.55 | 2023-2024 | Linzess |
| Xeris Pharmaceuticals, INC. | $40.51 | 2022-2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $37.45 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $34.93 | 2021 | |
| Corcept Therapeutics | $34.21 | 2025 | Korlym |
| Medline Industries LP | $26.73 | 2025 | |
| Jazz Pharmaceuticals INC. | $24.89 | 2022 | |
| Lundbeck LLC | $24.32 | 2022 | |
| Esperion Therapeutics, INC. | $21.11 | 2024 | Nexletol |
| Sumitomo Pharma America, INC. | $17.53 | 2025 | Gemtesa |
| Impel Pharmaceuticals INC. | $16.30 | 2022 | |
| Boston Scientific Corporation | $15.80 | 2023 | Watchman |
| Medtronic, INC. | $15.35 | 2022 | |
| Adlon Therapeutics L.P. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Self listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.